Perjeta (Pertuzumab) Injection 420 mb/14 mL (30 mg/mL)
Known name: Perjeta
Perjeta has firstly received its FDA approval in 2012 together with the chemotherapy drugs called Herceptin and Docetaxel in metastatic HER2 positive breast cancer. This method of application has been approved in our country in July 2016. In 2013, it was approved by FDA in the Neoadjuvant (minimizer = preparative) treatment of HER2 positive breast cancers developing regionally, however its use in this area has not yet been approved in our country.
Use of Perjeta is indicated up to the progression in combination with trastuzumab and docetaxel chemotherapy in the first series treatment in metastatic breast cancer which has not been previously treated with systemic chemotherapy or trastuzumab for the metastatic disease, has an ECOG performance score of 0-1 and HER-2/neu positive.
It cannot be continued as part of monotherapy or combination therapy in patients who has progression in receiving Perjeta treatment.
Perjeta cannot be used in patients who have used adjuvant or neoadjuvant trastuzumab within the first 12 months or in relapse or progression of the disease that develops after completion of trastuzumab treatment. Its use is indicated up to the progression in combination with Perjeta trastuzumab and docetaxel chemotherapy in relapse or progression of the disease that develops 12 months after completion of adjuvant or neoadjuvant trastuzumab therapy.
Perjeta (Pertuzumab) Injection 420 mb/14 mL (30 mg/mL) You can contact us to find out the price:Contact for detailed information